Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation.

Zhou S, Obianom ON, Huang J, Guo D, Yang H, Li Q, Shu Y

DOI: 10.3390/pharmaceutics13030330
Published: 2021 Mar 4
Container: Pharmaceutics
Publisher: Not recorded
Open access: yes

Credibility signals

serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/pharmaceutics13030330,
  title = {Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation.},
  author = {Zhou S and Obianom ON and Huang J and Guo D and Yang H and Li Q and Shu Y},
  year = {2021},
  journal = {Pharmaceutics},
  doi = {10.3390/pharmaceutics13030330},
  url = {https://doi.org/10.3390/pharmaceutics13030330}
}

RIS

TY  - JOUR
TI  - Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation.
AU  - Zhou S
AU  - Obianom ON
AU  - Huang J
AU  - Guo D
AU  - Yang H
AU  - Li Q
AU  - Shu Y
PY  - 2021
JO  - Pharmaceutics
DO  - 10.3390/pharmaceutics13030330
UR  - https://doi.org/10.3390/pharmaceutics13030330
ER  -

APA

S, Z., ON, O., J, H., D, G., H, Y., Q, L., & Y, S. (2021). Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation.. Pharmaceutics. https://doi.org/10.3390/pharmaceutics13030330

Source records

pubmed · retrieved 2026-09-25T07:39:02.132Z